Home    Back

Fresolimumab    (DrugBank: Fresolimumab)

3 diseases
IDDisease name (Link within this page)Number of trials
51Scleroderma1
222Primary nephrotic syndrome4
274Osteogenesis Imperfecta1

51. Scleroderma    [ 466 clinical trials,   536 drugs,   (DrugBank: 142 drugs),   110 drug target genes,   210 drug target pathways]
Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 466 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01284322
(ClinicalTrials.gov)		January 201125/1/2011Fresolimumab In Systemic SclerosisOPEN LABEL TRIAL OF ANTI-TGF-BETA MAB, FRESOLIMUMAB, IN SYSTEMIC SCLEROSIS - A PHASE ONE BIOMARKER TRIALDiffuse Systemic SclerosisDrug: FresolimumabBoston UniversityNULLCompleted18 YearsN/ABoth18Phase 1United States

222. Primary nephrotic syndrome    [ 234 clinical trials,   241 drugs,   (DrugBank: 78 drugs),   59 drug target genes,   185 drug target pathways]
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 234 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2012-002365-35-DE
(EUCTR)		15/07/201311/03/2013A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis Focal segmental glomerulosclerosis
MedDRA version: 14.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Not possible to specify		Product Name: Fresolimumab
Product Code: GC1008
INN or Proposed INN: Fresolimumab
Other descriptive name: GZ402669		Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes		125Phase 2France;United States;Brazil;Spain;Germany;Italy
2EUCTR2012-002365-35-IT
(EUCTR)		22/05/201320/03/2013A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis Focal segmental glomerulosclerosis
MedDRA version: 15.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Not possible to specify		Product Name: Fresolimumab
Product Code: GC1008
INN or Proposed INN: Fresolimumab
Other descriptive name: GZ402669		Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes		125Phase 2France;United States;Brazil;Spain;Germany;Italy
3EUCTR2012-002365-35-ES
(EUCTR)		19/04/201309/04/2013A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis Focal segmental glomerulosclerosis
MedDRA version: 14.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Not possible to specify		Product Name: Fresolimumab
Product Code: GC1008
INN or Proposed INN: Fresolimumab
Other descriptive name: GZ402669		Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes		125Phase 2France;United States;Brazil;Spain;Germany;Italy
4NCT01665391
(ClinicalTrials.gov)		August 201213/8/2012A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental GlomerulosclerosisPrimary Focal Segmental GlomerulosclerosisDrug: fresolimumab;Drug: PlaceboGenzyme, a Sanofi CompanyNULLCompleted18 YearsN/ABoth36Phase 2United States;Brazil;Germany;Italy;Spain

274. Osteogenesis Imperfecta    [ 78 clinical trials,   87 drugs,   (DrugBank: 19 drugs),   14 drug target genes,   74 drug target pathways]
Searched query = "Osteogenesis Imperfecta"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 78 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03064074
(ClinicalTrials.gov)		November 15, 201713/10/2016Safety of Fresolimumab in the Treatment of Osteogenesis ImperfectaMulticenter Study to Evaluate Safety of Fresolimumab in Adults With Moderate-to-severe Osteogenesis ImperfectaOsteogenesis ImperfectaDrug: FresolimumabBaylor College of MedicineGenzyme, a Sanofi Company;Shriners Hospitals for Children;Hugo W. Moser Research Institute at Kennedy Krieger, Inc.;Hospital for Special Surgery, New York;University of California, Los Angeles;University of Nebraska;Oregon Health and Science University;University of South FloridaRecruiting18 YearsN/AAll16Phase 1United States

Back to top